scholarly journals Information about Prostate Cancer for Urologist: Ga-68 Prostate Specific Membrane Antigen Positron Emission Tomography/Computed Tomography Scintigraphy

2016 ◽  
Vol 15 (4) ◽  
pp. 159-162
Author(s):  
Levent Kabasakal
Keyword(s):  
Prostate Cancer ◽  
Computed Tomography ◽  
Positron Emission Tomography ◽  
Emission Tomography ◽  
Prostate Specific Membrane Antigen ◽  
Positron Emission ◽  
Specific Membrane

scholarly journals 68Gallium-prostate-specific membrane antigen ligand positron-emission tomography or computed tomography in biochemical failure after radical prostatectomy: A case report

2017 ◽  
Vol 1 ◽  
pp. 3
Author(s):  
Irene A. Chidothe ◽  
David B. Anderson
Keyword(s):  
Prostate Cancer ◽  
Computed Tomography ◽  
Positron Emission Tomography ◽  
Case Report ◽  
Radical Prostatectomy ◽  
Biochemical Failure ◽  
Emission Tomography ◽  
Prostate Specific Membrane Antigen ◽  
Positron Emission ◽  
Specific Membrane

Biochemical failure after radical treatment for prostate cancer occurs in up to 30% – 50% of cases. Localisation of clinical disease is challenging because clinical symptoms often manifest long after the initial rise in prostate-specific antigen. The detection rates of imaging modalities such as contrasted computed tomography (CT), bone scan, magnetic resonance imaging and choline positron-emission tomography (PET) or CT, are limited. Prostate-specific membrane antigen (PSMA) ligand PET or CT is a novel imaging modality under investigation for various diagnostic and therapeutic indications in the management of prostate cancer. We present a case report illustrating how <sup><span style="font-size: small;">68</span></sup>Gallium-PSMA ligand PET or CT was used to guide management in a patient presenting with biochemical failure after radical prostatectomy.

Sign in / Sign up

Export Citation Format

Share Document